190 related articles for article (PubMed ID: 30425522)
1. Clinical characterization of
Liu Z; Wu L; Cao J; Yang Z; Zhou C; Cao L; Wu H; Shen H; Jin M; Zhang Y; Mao X; Xiang J; Ma K; Li B; Zhang T; Hu Y
Onco Targets Ther; 2018; 11():7323-7331. PubMed ID: 30425522
[TBL] [Abstract][Full Text] [Related]
2. EGFR and ERBB2 Exon 20 Insertion Mutations in Chinese Non-small Cell Lung Cancer Patients: Pathological and Molecular Characterization, and First-Line Systemic Treatment Evaluation.
Zhao R; Li J; Guo L; Xiang C; Chen S; Zhao J; Shao J; Zhu L; Ye M; Qin G; Chu T; Han Y
Target Oncol; 2024 Mar; 19(2):277-288. PubMed ID: 38416376
[TBL] [Abstract][Full Text] [Related]
3. Mutation Variants and Co-Mutations as Genomic Modifiers of Response to Afatinib in HER2-Mutant Lung Adenocarcinoma.
Fang W; Zhao S; Liang Y; Yang Y; Yang L; Dong X; Zhang L; Tang Y; Wang S; Yang Y; Ma X; Wang M; Wang W; Zhao S; Wang K; Gao S; Zhang L
Oncologist; 2020 Mar; 25(3):e545-e554. PubMed ID: 32162827
[TBL] [Abstract][Full Text] [Related]
4. Afatinib 30 mg in the treatment of common and uncommon
Qian J; Ye X; Huang A; Qin R; Cai Y; Xue Y; Zhang S; Wang W; Xiong L; Gu A
J Thorac Dis; 2022 Jun; 14(6):2169-2177. PubMed ID: 35813735
[TBL] [Abstract][Full Text] [Related]
5. Conformational Landscapes of HER2 Exon 20 Insertions Explain Their Sensitivity to Kinase Inhibitors in Lung Adenocarcinoma.
Zhao S; Fang W; Pan H; Yang Y; Liang Y; Yang L; Dong X; Zhan J; Wang K; Zhang L
J Thorac Oncol; 2020 Jun; 15(6):962-972. PubMed ID: 32036069
[TBL] [Abstract][Full Text] [Related]
6. Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas.
Costa DB; Jorge SE; Moran JP; Freed JA; Zerillo JA; Huberman MS; Kobayashi SS
J Thorac Oncol; 2016 Jun; 11(6):918-23. PubMed ID: 26964772
[TBL] [Abstract][Full Text] [Related]
7. Co-Occurring Alterations of ERBB2 Exon 20 Insertion in Non-Small Cell Lung Cancer (NSCLC) and the Potential Indicator of Response to Afatinib.
Yuan B; Zhao J; Zhou C; Wang X; Zhu B; Zhuo M; Dong X; Feng J; Yi C; Yang Y; Zhang H; Zhou W; Chen Z; Yang S; Ai X; Chen K; Cui X; Liu D; Shi C; Wu W; Zhang Y; Chang L; Li J; Chen R; Yang S
Front Oncol; 2020; 10():729. PubMed ID: 32477948
[No Abstract] [Full Text] [Related]
8. Treatment outcome and clinical characteristics of HER2 mutated advanced non-small cell lung cancer patients in China.
Xu F; Yang G; Xu H; Yang L; Qiu W; Wang Y
Thorac Cancer; 2020 Mar; 11(3):679-685. PubMed ID: 31975535
[TBL] [Abstract][Full Text] [Related]
9. A multicenter-retrospective study of non-small-cell lung carcinoma harboring uncommon epidermal growth factor receptor (EGFR) mutations: different subtypes of EGFR exon 19 deletion-insertions exhibit the clinical characteristics and prognosis of non-small cell lung carcinoma.
Chen Y; Xu J; Zhang L; Song Y; Wen W; Lu J; Zhao Z; Kong W; Liu W; Guo A; Santarpia M; Yamada T; Cai X; Yu Z
Transl Lung Cancer Res; 2022 Feb; 11(2):238-249. PubMed ID: 35280318
[TBL] [Abstract][Full Text] [Related]
10. Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review.
Burnett H; Emich H; Carroll C; Stapleton N; Mahadevia P; Li T
PLoS One; 2021; 16(3):e0247620. PubMed ID: 33684140
[TBL] [Abstract][Full Text] [Related]
11. Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program.
Peters S; Curioni-Fontecedro A; Nechushtan H; Shih JY; Liao WY; Gautschi O; Spataro V; Unk M; Yang JC; Lorence RM; Carrière P; Cseh A; Chang GC
J Thorac Oncol; 2018 Dec; 13(12):1897-1905. PubMed ID: 30096481
[TBL] [Abstract][Full Text] [Related]
12. HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib.
Zhang X; Lv J; Wu Y; Qin N; Ma L; Li X; Nong J; Zhang H; Zhang Q; Yang X; Shi H; Wang J; Zhang S
Front Oncol; 2020; 10():1162. PubMed ID: 32850330
[TBL] [Abstract][Full Text] [Related]
13. The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations.
Yang CJ; Tsai MJ; Hung JY; Lee MH; Tsai YM; Tsai YC; Hsu JF; Liu TC; Huang MS; Chong IW
BMC Pharmacol Toxicol; 2017 Dec; 18(1):82. PubMed ID: 29237484
[TBL] [Abstract][Full Text] [Related]
14. Specific
Yang G; Xu H; Hu J; Liu R; Hu P; Yang Y; Li W; Hao X; Zhang S; Xu F; Ai X; Li J; Wang Y
Front Pharmacol; 2022; 13():806737. PubMed ID: 35330827
[No Abstract] [Full Text] [Related]
15. Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial.
Goss GD; Felip E; Cobo M; Lu S; Syrigos K; Lee KH; Göker E; Georgoulias V; Li W; Guclu S; Isla D; Min YJ; Morabito A; Ardizzoni A; Gadgeel SM; Fülöp A; Bühnemann C; Gibson N; Krämer N; Solca F; Cseh A; Ehrnrooth E; Soria JC
JAMA Oncol; 2018 Sep; 4(9):1189-1197. PubMed ID: 29902295
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the effects of the three major tyrosine kinase inhibitors as first-line therapy for non-small-cell lung cancer harboring epidermal growth factor receptor mutations.
Tu CY; Chen CM; Liao WC; Wu BR; Chen CY; Chen WC; Hsia TC; Cheng WC; Chen CH
Oncotarget; 2018 May; 9(36):24237-24247. PubMed ID: 29849936
[TBL] [Abstract][Full Text] [Related]
17. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
Shen YC; Tseng GC; Tu CY; Chen WC; Liao WC; Chen WC; Li CH; Chen HJ; Hsia TC
Lung Cancer; 2017 Aug; 110():56-62. PubMed ID: 28676220
[TBL] [Abstract][Full Text] [Related]
18. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.
Yang JC; Sequist LV; Geater SL; Tsai CM; Mok TS; Schuler M; Yamamoto N; Yu CJ; Ou SH; Zhou C; Massey D; Zazulina V; Wu YL
Lancet Oncol; 2015 Jul; 16(7):830-8. PubMed ID: 26051236
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Pyrotinib in a Heavily Pretreated Patient with Lung Adenocarcinoma Harboring HER2 Amplification and Exon 20 Insertions: A Case Report.
Shan J; Ruan J; Tan Y; Yan L; Chen S; Du M; Wang L
Onco Targets Ther; 2020; 13():9849-9856. PubMed ID: 33061462
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of
Shi L; Xu C; Ma Y; Ou Q; Wu X; Lu S; Shao Y; Guo R; Kong J
ESMO Open; 2020 Nov; 5(6):e000985. PubMed ID: 33214226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
